Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler Acquires 172,900 Shares

Accelerate Diagnostics Inc (NASDAQ:AXDX) Director Jack W. Schuler acquired 172,900 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The shares were bought at an average price of $5.89 per share, for a total transaction of $1,018,381.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Accelerate Diagnostics stock traded up $0.59 during trading on Thursday, hitting $8.11. 15,305 shares of the stock were exchanged, compared to its average volume of 556,941. The company has a current ratio of 14.93, a quick ratio of 13.94 and a debt-to-equity ratio of 12.81. The company has a fifty day moving average price of $12.69 and a 200-day moving average price of $16.16. The stock has a market capitalization of $443.67 million, a price-to-earnings ratio of -5.44 and a beta of 2.97. Accelerate Diagnostics Inc has a 1-year low of $4.53 and a 1-year high of $24.00.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.04. Accelerate Diagnostics had a negative net margin of 903.51% and a negative return on equity of 469.38%. The business had revenue of $3.50 million during the quarter, compared to the consensus estimate of $3.53 million. Equities research analysts forecast that Accelerate Diagnostics Inc will post -1.52 EPS for the current fiscal year.

Several research analysts have recently weighed in on AXDX shares. Piper Sandler upped their price objective on Accelerate Diagnostics from to and gave the stock an “overweight” rating in a research report on Tuesday, January 14th. Zacks Investment Research raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 26th. ValuEngine cut shares of Accelerate Diagnostics from a “buy” rating to a “hold” rating in a report on Tuesday, February 4th. Finally, BidaskClub raised shares of Accelerate Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Accelerate Diagnostics currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its holdings in shares of Accelerate Diagnostics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 165,231 shares of the medical research company’s stock worth $2,793,000 after acquiring an additional 3,237 shares during the last quarter. State Street Corp boosted its holdings in shares of Accelerate Diagnostics by 6.2% during the 3rd quarter. State Street Corp now owns 586,952 shares of the medical research company’s stock worth $10,900,000 after buying an additional 34,039 shares during the period. First Trust Advisors LP grew its stake in Accelerate Diagnostics by 16.7% in the 3rd quarter. First Trust Advisors LP now owns 131,089 shares of the medical research company’s stock valued at $2,434,000 after buying an additional 18,757 shares during the last quarter. Raging Capital Management LLC grew its stake in Accelerate Diagnostics by 20.9% in the 3rd quarter. Raging Capital Management LLC now owns 56,398 shares of the medical research company’s stock valued at $1,047,000 after buying an additional 9,762 shares during the last quarter. Finally, PVG Asset Management Corp bought a new position in Accelerate Diagnostics in the 3rd quarter valued at about $366,000. Hedge funds and other institutional investors own 55.23% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Read More: What are no-load funds?

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.